Phio completes commercial-scale cGMP manufacturing for PH-762
Phio Pharmaceuticals reported Q3 2026 financial results and business updates, noting the commercial-scale cGMP batch release of PH-762 drug substance and submission of data to the FDA for a Phase 2b clinical study. This milestone marks progress toward initiating the upcoming clinical trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed